Eluxadoline (大腸躁鬱症) - 2023年為止的預測與市場分析
Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 58 Pages
|Eluxadoline (大腸躁鬱症) - 2023年為止的預測與市場分析 Eluxadoline (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年12月31日||內容資訊: 英文 58 Pages||
本報告提供大腸躁鬱症 (IBS) 治療藥物──Eluxadoline之相關調查，提供您疾病概要與免疫學，疾病管理，競爭情形，未滿足需求機會，開發平台評估，主要企業的資訊，今後的市場預測等資訊。
Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.
Eluxadoline is being developed for the treatment of IBS-D. As of October 2014, it had reached the Phase III stage of development, and also has been granted a Fast-Track designation by the FDA. Furiex Pharmaceuticals initially licensed eluxadoline from Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson [J&J]) for the development of the product. Subsequently, Furiex was fully-acquired by Actavis in July 2014 (Furiex Pharmaceuticals, press release, July 2, 2014).